SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”).
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
